Miguel Forte is the Chief Executive Officer of Zelluna Immunotherapy and currently Chief Commercialization Officer and Chair of the Commercialization Committee, International Society of Cellular Therapy. Formerly CMO, Bone Therapeutics SA and EVP and SVP of Clinical Development and Regulatory Affairs, COO and CMO of TxCell S.A. Miguel has extensive expertise in the regenerative medicine and cell therapy industries, as well as medical and regulatory affairs, ranging from leading early and late stage clinical trials to market authorization and the launch of new biologic products for various indications.
Notably, he contributed to TxCell’s transformation from a science based organization into a quoted cell therapy company, participating in several rounds of investment including the IPO of TxCell in 2014, and led multiple discussions, implementations and executions around major commercial and scientific partnerships. Held various senior positions at the European Medicines Agency, Bristol-Myers Squibb, Abbott and Wellcome Laboratories (now part of GSK), International Medical, Nabi Pharmaceuticals and UCB. Miguel has an M.D. (University of Lisbon), a Ph.D. in Immunology (University of Birmingham) and a Certificate on Health Economics of Pharmaceuticals (HEP) from the Stockholm School of Economics. He is also an Associate Professor in Health Sciences and Pharmacy at the University of Aveiro and the University of Lisbon and Fellow of the Faculty of Pharmaceutical Medicine of the RCP (UK).